All In Biotech

Drug Trial Radar · NCT06579105

Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

A Phase IIb, Randomized, Double-blind, Placebo-controlled and Open-label Active Comparator Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Adults With Type 2 Diabetes Mellitus.

Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 406 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

406

Actual

Start

Oct 8, 2024

Primary completion

Dec 19, 2025

Study completion Dec 19, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Placebo (placebo matching AZD5004 film-coated tablet)Drug

    Placebo film-coated tablet (matching AZD5004)

  • AZD5004Drug

    AZD5004 film-coated tablet, once daily during 26 weeks

  • SemaglutideDrug

    3-14 mg tablets of Semaglutide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1cTime frame: Baseline to Week 26

Locations

97 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Mobile, Alabama

  • Research Site

    Sheffield, Alabama

  • Research Site

    Vestavia Hills, Alabama

  • Research Site

    Tucson, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    Sacramento, California

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Lake City, Florida

  • Research Site

    Largo, Florida

  • Research Site

    Ocoee, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Decatur, Georgia

  • Research Site

    Savannah, Georgia

  • Research Site

    Lombard, Illinois

  • Research Site

    Potomac, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Roslindale, Massachusetts

  • Research Site

    Farmington Hills, Michigan

  • Research Site

    Gulfport, Mississippi

  • Research Site

    Kansas City, Missouri

  • Research Site

    Omaha, Nebraska

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Albuquerque, New Mexico

  • Research Site

    Binghamton, New York

  • Research Site

    Durham, North Carolina

  • Research Site

    Greensboro, North Carolina

  • Research Site

    Rocky Mount, North Carolina

  • Research Site

    Statesville, North Carolina

  • Research Site

    Wilmington, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Fargo, North Dakota

  • Research Site

    Beachwood, Ohio

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Medford, Oregon

  • Research Site

    West Chester, Pennsylvania

  • Research Site

    Gaffney, South Carolina

  • Research Site

    Bristol, Tennessee

Showing 40 of 97 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.